All the news Showing 10 of 23 articles from: New to treatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Grazoprevir / elbasvir highly effective in previously untreated hepatitis C Keith Alcorn / 24 April 2015 A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with gentoypes 1, 4 or 6 hepatitis C infection, according to results of the C-EDGE trial, ... MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C Keith Alcorn / 22 April 2014 A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode reported on Friday at the ... BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks Caspar Thomson / 17 April 2014 A combination of two direct-acting antivirals developed by Bristol-Myers Squibb (BMS) cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the need for pegylated interferon ... Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients Liz Highleyman / 16 April 2014 A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including ... European liver specialists recommend use of newest hepatitis C drugs Keith Alcorn / 12 April 2014 The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with ... Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection Merck press release / 11 April 2014 New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) Medivir press release / 17 March 2014 US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive